<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04320264</url>
  </required_header>
  <id_info>
    <org_study_id>UMCIRB 19-000914</org_study_id>
    <nct_id>NCT04320264</nct_id>
  </id_info>
  <brief_title>Metabolic Inflexibility is Related to Elevated Muscle Anaerobic Glycolysis</brief_title>
  <official_title>Metabolic Inflexibility is Related to Elevated Muscle Anaerobic Glycolysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>East Carolina University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>East Carolina University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The focus of this proposal is on overweight (25&gt;BMI&lt;30 kg/m2) subjects, as these individuals&#xD;
      exhibit a high risk of becoming obese and/or developing metabolic diseases. We hypothesize&#xD;
      that in some overweight individuals there is a &quot;metabolic program&quot; in skeletal muscle which&#xD;
      predisposes them to the development of obesity. Findings may lead to clinical screening tools&#xD;
      for determining risk for obesity in non-obese individuals and targeting this group for&#xD;
      prevention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our overall hypothesis is that increased reliance on anaerobic glycolysis in muscle shifts&#xD;
      fasting metabolism from fat towards carbohydrate utilization, which results in metabolic&#xD;
      inflexibility and subsequent metabolic disease (i.e. obesity). To test our hypothesis,&#xD;
      overweight subjects (BMI 25 to 30 kg/m2) will be recruited and screened for reliance on&#xD;
      anaerobic glycolysis (resting/fasting plasma lactate concentrations). Subjects with high (top&#xD;
      quartile) and low (bottom quartile) resting/fasting plasma lactate will be chosen. The&#xD;
      premise of this screening is that subjects with low lactate will have high muscle aerobic&#xD;
      substrate oxidation, while those with elevated lactate will have low muscle oxidative&#xD;
      metabolism. Severely obese subjects will be studied as a comparator group. In aim 1 in vivo&#xD;
      muscle lactate release and respiratory exchange ratio (RER) will be determined to investigate&#xD;
      if subjects with high reliance on anaerobic glycolysis exhibit a shift towards carbohydrate&#xD;
      utilization at the whole-body level. Aim 2 will test whether subjects with elevated reliance&#xD;
      on anaerobic glycolysis in muscle are metabolically inflexible. To establish causality, aim 3&#xD;
      is designed to follow subjects after an intervention that shifts skeletal muscle metabolism&#xD;
      from carbohydrate to fat utilization. Our preliminary findings indicate that bariatric&#xD;
      surgery normalizes muscle lactate production; therefore, severely obese subjects will be&#xD;
      studied before and after gastric bypass surgery (aim 3).&#xD;
&#xD;
      The study (MetFlex) will enroll 74 adults; (Group 1) 60 overweight (BMI 25 to 30 kg/m2) males&#xD;
      and females ages 18-50 years old and (Group 2) 14 severely obese (BMI 40 to 50 kg/m2) adult&#xD;
      females who are scheduled for bariatric surgery.&#xD;
&#xD;
      Endpoints to be investigated in the 3 specific aims.&#xD;
&#xD;
      Carbohydrate/fat oxidation (RER) in the fasting condition. High lactate vs low lactate groups&#xD;
      (aim 1). Pre-surgery vs post-surgery (aim 3)&#xD;
&#xD;
      Muscle oxygen consumption (substrate oxidation) in the fasting condition. High lactate vs low&#xD;
      lactate groups (aim 1). Pre-surgery vs post-surgery (aim 3)&#xD;
&#xD;
      Muscle lactate release in the fasting condition. High lactate vs low lactate groups (aim 1).&#xD;
      Pre-surgery vs post-surgery (aim 3)&#xD;
&#xD;
      Endogenous glucose production in the fasting condition. High lactate vs low lactate groups&#xD;
      (aim 1). Pre-surgery vs post-surgery (aim 3)&#xD;
&#xD;
      Insulin sensitivity (clamp M value). High lactate vs low lactate groups (aim 1)&#xD;
&#xD;
      Change in Carbohydrate/fat oxidation (RER) in response to glucose + insulin (metabolic&#xD;
      flexibility). High lactate vs low lactate groups (aim 2)&#xD;
&#xD;
      Change in muscle fat oxidation in response to high fat feeding (metabolic flexibility). High&#xD;
      lactate vs low lactate groups (aim 2)&#xD;
&#xD;
      Change in muscle oxygen consumption (substrate oxidation) in response to high fat feeding&#xD;
      (metabolic flexibility). High lactate vs low lactate groups (aim 2)&#xD;
&#xD;
      Our basic premise is that elevated fasting plasma lactate causes glucose production to be&#xD;
      increased and that a &quot;Vicious Cori cycle&quot; is the underlying cause of the metabolic syndrome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Carbohydrate/fat oxidation (RER) in the fasting condition.</measure>
    <time_frame>Years 1-5</time_frame>
    <description>RER will be measured from indirect calorimetry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle oxygen consumption (substrate oxidation) in the fasting condition.</measure>
    <time_frame>Years 1-5</time_frame>
    <description>Muscle oxygen consumption will be measured by near-infrared spectroscopy (NIRS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle lactate release in the fasting condition.</measure>
    <time_frame>Years 1-5</time_frame>
    <description>Muscle lactate release will be measured by microdialysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Carbohydrate/fat oxidation (RER) in response to glucose + insulin (metabolic flexibility)</measure>
    <time_frame>Years 1-5</time_frame>
    <description>Indirect calorimetry during glucose clamp</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in muscle fat oxidation in response to high fat feeding (metabolic flexibility).</measure>
    <time_frame>Years 1-5</time_frame>
    <description>Oxidation of fatty acid in muscle homogenate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in muscle oxygen consumption (substrate oxidation) in response to high fat feeding (metabolic flexibility).</measure>
    <time_frame>Years 1-5</time_frame>
    <description>Oxygen consumption measured by near-infrared spectroscopy (NIRS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity (clamp M value).</measure>
    <time_frame>Years 1-5</time_frame>
    <description>Measured during glucose clamp.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endogenous glucose production in the fasting condition.</measure>
    <time_frame>Years 1-5</time_frame>
    <description>Measured with isotopically labeled glucose</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Metabolic Inflexibility</condition>
  <arm_group>
    <arm_group_label>Low oxidizers/high lactate</arm_group_label>
    <description>Individuals with low aerobic oxidation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High oxidizers/low lactate</arm_group_label>
    <description>Individuals with high aerobic oxidation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese</arm_group_label>
    <description>Severely obese scheduled for surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Weight loss surgery</intervention_name>
    <description>Severely obese women (BMI &gt;40) undergo sleeve gastrectomy</description>
    <arm_group_label>Obese</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and tissue samples without analysis of DNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        High oxidizers Low oxidizers Obese&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-50 years old&#xD;
&#xD;
          -  BMI of 25 - 30 kg/m2&#xD;
&#xD;
          -  BMI &gt; 40kg/m2&#xD;
&#xD;
          -  Lactate levels in top and lower 25%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Mentally disabled&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Smokers&#xD;
&#xD;
          -  Subjects with heart disease&#xD;
&#xD;
          -  Type 1 and 2 diabetes&#xD;
&#xD;
          -  Endocrine disease&#xD;
&#xD;
          -  Hypertension&#xD;
&#xD;
          -  Musculoskeletal disease&#xD;
&#xD;
          -  Peripheral occlusion&#xD;
&#xD;
          -  Hepatic disease&#xD;
&#xD;
          -  Have had weight fluctuations exceeding + 3% in the previous 12 months&#xD;
&#xD;
          -  On medications which alter carbohydrate metabolism will not be studied&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Terry Jones, PhD</last_name>
    <phone>2527446249</phone>
    <email>joneste@ecu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gerald L Dohm, PhD</last_name>
    <phone>2527442682</phone>
    <email>dohmg@ecu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terry Jones, PhD</last_name>
      <phone>252-744-6249</phone>
      <email>joneste@ecu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Gerald L Dohm, PhD</last_name>
      <phone>2527442682</phone>
      <email>dohmg@ecu.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ryan TE, Brophy P, Lin CT, Hickner RC, Neufer PD. Assessment of in vivo skeletal muscle mitochondrial respiratory capacity in humans by near-infrared spectroscopy: a comparison with in situ measurements. J Physiol. 2014 Aug 1;592(15):3231-41. doi: 10.1113/jphysiol.2014.274456. Epub 2014 Jun 20.</citation>
    <PMID>24951618</PMID>
  </reference>
  <reference>
    <citation>Fisher-Wellman KH, Davidson MT, Narowski TM, Lin CT, Koves TR, Muoio DM. Mitochondrial Diagnostics: A Multiplexed Assay Platform for Comprehensive Assessment of Mitochondrial Energy Fluxes. Cell Rep. 2018 Sep 25;24(13):3593-3606.e10. doi: 10.1016/j.celrep.2018.08.091.</citation>
    <PMID>30257218</PMID>
  </reference>
  <reference>
    <citation>Chondronikola M, Magkos F, Yoshino J, Okunade AL, Patterson BW, Muehlbauer MJ, Newgard CB, Klein S. Effect of Progressive Weight Loss on Lactate Metabolism: A Randomized Controlled Trial. Obesity (Silver Spring). 2018 Apr;26(4):683-688. doi: 10.1002/oby.22129. Epub 2018 Feb 24.</citation>
    <PMID>29476613</PMID>
  </reference>
  <reference>
    <citation>Goodpaster BH, Sparks LM. Metabolic Flexibility in Health and Disease. Cell Metab. 2017 May 2;25(5):1027-1036. doi: 10.1016/j.cmet.2017.04.015. Review.</citation>
    <PMID>28467922</PMID>
  </reference>
  <reference>
    <citation>Galgani JE, Moro C, Ravussin E. Metabolic flexibility and insulin resistance. Am J Physiol Endocrinol Metab. 2008 Nov;295(5):E1009-17. doi: 10.1152/ajpendo.90558.2008. Epub 2008 Sep 2. Review.</citation>
    <PMID>18765680</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 3, 2019</study_first_submitted>
  <study_first_submitted_qc>March 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2020</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metabolic Inflexibility</keyword>
  <keyword>Obesity</keyword>
  <keyword>Anaerobic glycolysis</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

